27 products were found matching "925,"!

Description: AMG 925 HCl is a selective and potent dual inhibitor of FLT3 (IC50: 2±1 nM) and CDK4 (IC50: 3±1 nM). Target: Others. Smiles: N(C=1N=C2N(C=3C(C2=CN1)=CC=NC3)[C@H]4CC[C@H](C)CC4)C=5N=C6C(=CC5)CN(C(CO)=O)CC6.Cl

Description: AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively. Target: CDK, FLT. Smiles: C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12. References: Xiaoqi Chen, et al. Fused tricyclic dual inhibitors of cdk 4/6 and flt3. WO 2012129344 A1

AMG 925 is a dual inhibitor of FMS-related tyrosine kinase 3 (FLT3) and cyclin-dependent kinase 4 (Cdk4, IC50s = 1 and 3 nM, respectively). It is selective for FLT3 and Cdk4 over Cdk1 (IC50 = 2.22 µM). AMG 925 also binds to FLT3ITD, FLT3D835Y, FLT3D835H, FLT3K663Q, and FLT3N841I (Kds = 1-4 nM). It inhibits...

Description: ADR-925 (ICRF 198), an active chelated iron metabolite of dexrazoxane, has the ability to protect neonatal rat cardiomyocytes from adriamycin-induced injury. Target: Endogenous Metabolite. Smiles: N([C@H](CN(CC(N)=O)CC(O)=O)C)(CC(N)=O)CC(O)=O. References: Jirkovský E, et al. Pharmacokinetics of the...

Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat. It is converted to moexiprilat in vivo by side chain ester hydrolysis. Moexipril inhibits ACE in a cell-free assay (IC50 = 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for...

PathPlex Panel 7 identifies total cytotoxic T-cells (CD8), T-helper cells (CD4), memory T-cells (CD45RO) and regulatory T-cells (FoxP3) within the context of the tumor microenvironment. Tumor cells are identified by cytokeratin.

PathPlex Panel 4 identifies total T-cells (CD3), cytotoxic T-cells (CD8) and regulatory T-cells (FoxP3) within the context of the tumor microenvironment. Antigen presenting cells such as macrophages (CD68) or tumor cells (cytokeratin) express immune checkpoint ligands such as PD-L1 which inhibits the ability of...

PathPlex Panel 5 identifies total T-cells (CD3), cytotoxic T-cells (CD8) and cells expressing the immune checkpoint ligand PD-L1 within the context of the tumor microenvironment. PD-L1 can be expressed on antigen presenting cells such as macrophages (CD68) or tumor cells (cytokeratin). Ki-67 is a proliferation...

PathPlex Panel 8 identifies total T-cells (CD3), T-helper cells (CD4), cytotoxic T-cells (CD8) and regulatory T-cells (FoxP3) within the tumor microenvironment. Lag3 is a checkpoint inhibitor which identifies exhausted T-cells. Tumor cells are identified by cytokeratin.

PathPlex Panel 6 identifies total T-cells (CD3) and cytotoxic T-cells (CD8) and activated cytotoxic T-cells (Granzyme B) within the tumor microenvironment. The inclusion of multiple tumor cell makers (cytokeratin, Sox10 and Ki-67) provides flexibility across multiple tumor types.

Description: ABT-925 is a selective dopamine D3 receptor (DRD3) antagonist with an in vitro affinity approximately 100 times higher for dopamine D3 receptors than for D2 receptors. Target: Others. Smiles: OC(/C=C/C(O)=O)=O.FC(F)(C1=CC(N2CCN(CC2)CCCSC(N3)=NC=CC3=O)=NC(C(C)(C)C)=N1)F.O.O. References: Pich EM, Collo G....

Description: ABT-925, also known as A-37203, BSF-201640, DAT-201, Lu-201640, and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D3 versus D2 receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D3...